The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent Heart Failure and Death in Patients with Stable Coronary Artery Disease: The Heart and Soul Study
Overview
Authors
Affiliations
Background: The N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) is a powerful predictor of adverse outcomes in patients with coronary artery disease (CAD). However, little is known regarding the prognostic significance of longitudinal changes in NT-proBNP levels.
Methods: We evaluated the ability of 5-year changes in NT-proBNP levels to predict subsequent heart failure (HF) hospitalization or cardiovascular (CV) death in 635 participants with stable CAD enrolled in the Heart and Soul Study.
Results: The median (IQR) 5-year change in NT-proBNP was 50 pg/mL (-5 to +222). During an average of 4.0 ± 1.4 years follow-up (i.e., 9 years from the baseline measurement), there were 67 events. Participants with 5-year changes in the highest quartile (≥ 223 pg/mL increase in NT-proBNP) had an almost 4-fold greater risk of subsequent HF or CV death than those in the lowest quartile of ≤-5 pg/mL (HR 3.8; 95% CI 2.0-7.3; p < 0.001). This association remained strong after adjustment for demographic variables, comorbidities, left ventricular mass index, systolic and diastolic function, and baseline and follow-up NT-proBNP levels (HR 3.9; 95% CI 1.1-13.4; p = 0.01).
Conclusion: Changes in NT-proBNP levels at 5 years predict subsequent HF or CV death in patients with stable CAD, independent of other prognostic markers, including baseline and follow-up NT-proBNP levels. A stable NT-proBNP level predicts a low risk of subsequent events.
Biomarkers for Heart Failure Prediction and Prevention.
Kotta P, Nambi V, Bozkurt B J Cardiovasc Dev Dis. 2023; 10(12).
PMID: 38132656 PMC: 10744096. DOI: 10.3390/jcdd10120488.
Jia X, Al Rifai M, Hoogeveen R, Echouffo-Tcheugui J, Shah A, Ndumele C JAMA Cardiol. 2023; 8(3):222-230.
PMID: 36753229 PMC: 9909572. DOI: 10.1001/jamacardio.2022.5309.
Conventional Biomarkers for Predicting Clinical Outcomes in Patients with Heart Disease.
Manescu I, Pal K, Lupu S, Dobreanu M Life (Basel). 2022; 12(12).
PMID: 36556477 PMC: 9781565. DOI: 10.3390/life12122112.
Prevalence and Prognostic Value of Heart Failure Stages: An Elderly Inpatient Based Cohort Study.
Zheng P, Yao S, Guo D, Cui L, Miao G, Dong W Front Med (Lausanne). 2021; 8:639453.
PMID: 33968953 PMC: 8100028. DOI: 10.3389/fmed.2021.639453.
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.
Schmitt W, Ruhs H, Burghaus R, Diedrich C, Duwal S, Eissing T Clin Pharmacol Ther. 2021; 110(2):498-507.
PMID: 33630302 PMC: 8360001. DOI: 10.1002/cpt.2222.